Risperidone and risk of gynecomastia in young men

Journal of Child and Adolescent Psychopharmacology

Volumn 25, Issue 9, 2015, Pages 671-673

  Etminan, Mahyar ^a,b   Carleton, Bruce ^a,b   Brophy, James M ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; GYNECOMASTIA; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; CHEMICALLY INDUCED; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; GYNECOMASTIA; HUMANS; MALE; RISK; RISPERIDONE; YOUNG ADULT;

EID: 84947918354     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2015.0024     Document Type: Article

References (13)

1. Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA: Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 19:373-382, 2009.
2. Essebag V, Genest J Jr, Suissa S, Pilote L: The nested case-control study in cardiology. Am Heart J 146:581-590, 2003.
3. Etminan M, Heran B, Carleton B, Brophy JM: Risperidone use and risk for gynecomastia in men. J Clin Psychopharmacol 34:656-657, 2014.
4. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C: Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362-1369, 2003.
5. Harlan WR, Grillo GP, Cornoni-Huntley J, Leaverton PE: Secondary sex characteristics of boys 12 to 17 years of age: The U.S. Health Examination Survey. J Pediatr 95:293-297, 1979.
6. Kinsella C Jr, Landfair A, Rottgers SA, Cray JJ, Weidman C, De-leyiannis FW, Grunwaldt L, Losee JE: The psychological burden of idiopathic adolescent gynecomastia. Plast Reconstr Surg 129:1-7, 2012.
7. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Bercher M: Prolactin levels and adverse events in patients treated with risper-idone. J Clin Psychopharmacol 19:57-61, 1999.
8. Leucht S, Cipriani A, Geddes JR: Comparative efficacy and tolera-bility of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 382:951-962, 2013.
9. LifeLink Health Plan Claims Database: Overview and study design issues. Little Rock, AR: University of Arkansas for Medical Sciences; 2010. Available at www.uams.edu/TRI/hsrcore/Lifelink-Health- Plan-Claims-Data-DesignIssues-wcost-April2010[1].pdf Accessed December 23, 2014.
10. Markowitz JS, Brown CS, Moore TR: Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 33:73-85, 1999.
11. Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in boys. Arch Dis Child 45:13-23, 1970.
12. Roke Y, Buitelaar JK, Boot AM, Tenback D, van Harten PN: Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. J Child Adolesc Psychopharmacol 22:432-439, 2012.
13. Szarfman A, Tonning JM, Levine JG, Doraiswamy PM: Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 26:748-758, 2006.